Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 27182063.
- Also identified by DOI 10.3899/jrheum.151252.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To report the efficacy and safety of tocilizumab (TCZ) for giant cell arteritis (GCA). A retrospective multicenter study that included 34 patients receiving TCZ for GCA. TCZ was effective in all but 6 patients, who still had mild symptoms. Mean glucocorticoid dose was tapered. One patient died and 3 patients had to stop TCZ therapy because of severe adverse events. Twenty-three patients stopped treatment; 8 of these experienced relapses after a mean of 3.5 ± 1.3 months. TCZ is effective in GCA. However, side effects occur. Whether this treatment has only a suspensive effect remains to be determined.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Giant Cell Arteritis
- Immunosuppressive Agents